Targeting oncogenic ALK: a promising strategy for cancer treatment.

Thumbnail Image
Identifiers
URI: https://hdl.handle.net/10641/3810
ISSN: 1538-8514
DOI: 10.1158/1535-7163.MCT-10-0615

Publication date

2011

Start date of the public exhibition period

End date of the public exhibition period

Authors

Advisors

Journal Title

Journal ISSN

Volume Title

Publisher

Metrics
Google Scholar
Share
Export

Research Projects

Organizational Units

Journal Issue

Abstract

Recently, the anaplastic lymphoma kinase (ALK) has been found to be altered in several solid and hematologic tumors. Novel drugs targeting this tyrosine kinase receptor are under development, and early clinical trials are showing promising activity in non-small cell lung cancer patients with ALK+ tumors. Here, we review the structure and function of the ALK receptor, the mechanisms associated with its deregulation in cancer, methods for ALK detection in tumor samples, its potential as a new marker for candidate patient selection for tailored therapy, and novel drugs under development that target ALK.

Doctoral program

Description

Keywords

Citation

Collections

FACULTAD DE MEDICINA